H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $25

H.C. Wainwright analyst Robert Burns maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 24.0

moomoo NewsJun 6 06:33 ET

ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment

ArriVent BioPharma (AVBP) said Wednesday that it signed a collaboration agreement with Alphamab Oncology's Jiangsu Alphamab Biopharmaceuticals unit to discover, develop, and commercialize antibody dru

MT NewswiresJun 5 11:26 ET

Express News | ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M

BenzingaJun 5 07:09 ET

Express News | Arrivent Announces a Multi-Target ADC Collaboration With Alphamab

ReutersJun 5 07:00 ET

Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products

ReutersJun 5 05:01 ET

Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements

TipRanksMay 20 08:25 ET